Prognostic implication of outpatient loop diuretic dose intensification trajectories in patients with chronic heart failure

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS IJC Heart and Vasculature Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI:10.1016/j.ijcha.2025.101632
Toshiharu Koike , Atsushi Suzuki , Noriko Kikuchi , Asami Yoshimura , Kaoru Haruki , Ayano Yoshida , Maiko Sone , Mayui Nakazawa , Kei Tsukamoto , Yasutaka Imamura , Hidetoshi Hattori , Tomohito Kogure , Junichi Yamaguchi , Tsuyoshi Shiga
{"title":"Prognostic implication of outpatient loop diuretic dose intensification trajectories in patients with chronic heart failure","authors":"Toshiharu Koike ,&nbsp;Atsushi Suzuki ,&nbsp;Noriko Kikuchi ,&nbsp;Asami Yoshimura ,&nbsp;Kaoru Haruki ,&nbsp;Ayano Yoshida ,&nbsp;Maiko Sone ,&nbsp;Mayui Nakazawa ,&nbsp;Kei Tsukamoto ,&nbsp;Yasutaka Imamura ,&nbsp;Hidetoshi Hattori ,&nbsp;Tomohito Kogure ,&nbsp;Junichi Yamaguchi ,&nbsp;Tsuyoshi Shiga","doi":"10.1016/j.ijcha.2025.101632","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The relationship between outpatient oral loop diuretic (OLD) dose intensification trajectories and the prognosis of patients with chronic heart failure (CHF) remains unclear.</div></div><div><h3>Methods</h3><div>In 832 patients with CHF, OLD dose trajectories for 1 year were consecutively investigated. OLD dose intensification was defined as the first occurrence of OLD dose increase from the baseline within the first year. Patients were classified into three groups of OLD dose intensification trajectories: irreversible, reversible, and no intensification. Irreversible intensification was defined as an OLD dose intensification wherein the dose remained above the baseline during the first year of follow-up. Reversible intensification referred to an OLD dose intensification wherein the dose returned to or dropped below the baseline within the first year of follow-up. No intensification was defined as no OLD dose intensification throughout the first year of follow-up. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular death (CVD), heart failure hospitalisation (HFH), a composite of CVD or HFH, and a composite of all-cause mortality or HFH after 1 year.</div></div><div><h3>Results</h3><div>During the median follow-up (57 [range, 13–102] months), 146 patients died. Irreversible intensification was associated with higher risks of all outcomes than no intensification (e.g., all-cause mortality: hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.08–2.44; HFH: HR, 2.16; 95% CI, 1.65–2.98; CVD or HFH: HR, 2.17; 95% CI, 1.59–2.96). Conversely, reversible intensification had comparable prognoses for all outcomes to no intensification.</div></div><div><h3>Conclusion</h3><div>OLD dose intensification trajectories could stratify the prognosis of CHF patients.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"57 ","pages":"Article 101632"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJC Heart and Vasculature","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352906725000351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The relationship between outpatient oral loop diuretic (OLD) dose intensification trajectories and the prognosis of patients with chronic heart failure (CHF) remains unclear.

Methods

In 832 patients with CHF, OLD dose trajectories for 1 year were consecutively investigated. OLD dose intensification was defined as the first occurrence of OLD dose increase from the baseline within the first year. Patients were classified into three groups of OLD dose intensification trajectories: irreversible, reversible, and no intensification. Irreversible intensification was defined as an OLD dose intensification wherein the dose remained above the baseline during the first year of follow-up. Reversible intensification referred to an OLD dose intensification wherein the dose returned to or dropped below the baseline within the first year of follow-up. No intensification was defined as no OLD dose intensification throughout the first year of follow-up. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular death (CVD), heart failure hospitalisation (HFH), a composite of CVD or HFH, and a composite of all-cause mortality or HFH after 1 year.

Results

During the median follow-up (57 [range, 13–102] months), 146 patients died. Irreversible intensification was associated with higher risks of all outcomes than no intensification (e.g., all-cause mortality: hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.08–2.44; HFH: HR, 2.16; 95% CI, 1.65–2.98; CVD or HFH: HR, 2.17; 95% CI, 1.59–2.96). Conversely, reversible intensification had comparable prognoses for all outcomes to no intensification.

Conclusion

OLD dose intensification trajectories could stratify the prognosis of CHF patients.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性心力衰竭患者门诊襻利尿剂剂量强化轨迹的预后意义
背景门诊口服利尿剂(OLD)剂量强化轨迹与慢性心力衰竭(CHF)患者预后之间的关系尚不清楚。方法对832例CHF患者连续1年的OLD剂量轨迹进行研究。OLD剂量增强被定义为在第一年内首次出现OLD剂量从基线增加。患者按照OLD剂量增强轨迹分为三组:不可逆、可逆和无增强。不可逆强化被定义为在随访的第一年剂量仍高于基线的OLD剂量强化。可逆强化是指在随访的第一年内剂量恢复到或降到基线以下的OLD剂量强化。无强化被定义为在随访的第一年没有OLD剂量强化。主要结局为全因死亡率。次要结局是心血管死亡(CVD)、心力衰竭住院(HFH)、CVD或HFH复合、1年后全因死亡率或HFH复合。结果在中位随访期间(57个月,13-102个月),146例患者死亡。不可逆强化与所有结局的风险均高于无强化(例如,全因死亡率:风险比[HR]为1.63;95%置信区间[CI], 1.08-2.44;Hfh: hr, 2.16;95% ci, 1.65-2.98;CVD或HFH: HR, 2.17;95% ci, 1.59-2.96)。相反,可逆强化与无强化的预后相当。结论old剂量强化轨迹可对CHF患者的预后进行分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
IJC Heart and Vasculature
IJC Heart and Vasculature Medicine-Cardiology and Cardiovascular Medicine
CiteScore
4.90
自引率
10.30%
发文量
216
审稿时长
56 days
期刊介绍: IJC Heart & Vasculature is an online-only, open-access journal dedicated to publishing original articles and reviews (also Editorials and Letters to the Editor) which report on structural and functional cardiovascular pathology, with an emphasis on imaging and disease pathophysiology. Articles must be authentic, educational, clinically relevant, and original in their content and scientific approach. IJC Heart & Vasculature requires the highest standards of scientific integrity in order to promote reliable, reproducible and verifiable research findings. All authors are advised to consult the Principles of Ethical Publishing in the International Journal of Cardiology before submitting a manuscript. Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression.
期刊最新文献
Differential effects of non-selective and cardio-selective beta-blocker therapy on ECG parameters in long QT syndrome type 1 Exercise-induced ventricular changes in recreational half-marathon runners compared with marathon/ultramarathon runners Heart failure etiology and lipoprotein subfractions: Insight from the SMARTEX-HF study Echocardiographic strain imaging and progression of atrial fibrillation in low-risk individuals Effects of atrial fibrillation on cerebral perfusion and cognitive function: A systematic review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1